|
1
|
Di Micco R, Krizhanovsky V, Baker D and
d'Adda di Fagagna F: Cellular senescence in ageing: From mechanisms
to therapeutic opportunities. Nat Rev Mol Cell Biol. 22:75–95.
2021.
|
|
2
|
Munoz-Espin D and Serrano M: Cellular
senescence: From physiology to pathology. Nat Rev Mol Cell Biol.
15:482–496. 2014.
|
|
3
|
Hernandez-Segura A, Nehme J and Demaria M:
Hallmarks of cellular senescence. Trends Cell Biol. 28:436–453.
2018.
|
|
4
|
Hu D, Yuan S, Zhong J, Liu Z, Wang Y, Liu
L, Li J, Wen F, Liu J and Zhang J: Cellular senescence and
hematological malignancies: From pathogenesis to therapeutics.
Pharmacol Ther. 223:1078172021.
|
|
5
|
Fane M and Weeraratna AT: How the ageing
microenvironment influences tumour progression. Nat Rev Cancer.
20:89–106. 2020.
|
|
6
|
Davalos AR, Coppe JP, Campisi J and
Desprez PY: Senescent cells as a source of inflammatory factors for
tumor progression. Cancer Metastasis Rev. 29:273–283. 2010.
|
|
7
|
Hao X, Wang C and Zhang R: Chromatin basis
of the senescence-associated secretory phenotype. Trends Cell Biol.
32:513–526. 2022.
|
|
8
|
Yin Y, Chen H, Wang Y, Zhang L and Wang X:
Roles of extracellular vesicles in the aging microenvironment and
age-related diseases. J Extracell Vesicles. 10:e121542021.
|
|
9
|
Newell GR, Spitz MR and Sider JG: Cancer
and age. Semin Oncol. 16:3–9. 1989.
|
|
10
|
Gopas J, Stern E, Zurgil U, Ozer J,
Ben-Ari A, Shubinsky G, Braiman A, Sinay R, Ezratty J, Dronov V, et
al: Reed-Sternberg cells in Hodgkin's lymphoma present features of
cellular senescence. Cell Death Dis. 7:e24572016.
|
|
11
|
Aouali N, Eddabra L, Macadre J and Morjani
H: Immunosuppressors and reversion of multidrug-resistance. Crit
Rev Oncol Hematol. 56:61–70. 2005.
|
|
12
|
Kang YK, Zhan Z, Regis J, Alvarez M, Robey
R, Meadows B, Dickstein B, Lee JS, Otsuki T, Stetler-Stevenson M,
et al: Expression of mdr-1 in refractory lymphoma: quantitation by
polymerase chain reaction and validation of the assay. Blood.
86:1515–1524. 1995.
|
|
13
|
Karai E, Szebenyi K, Windt T, Feher S,
Szendi E, Dekay V, Vajdovich P, Szakacs G and Furedi A: Celecoxib
prevents doxorubicin-induced multidrug resistance in canine and
mouse lymphoma cell lines. Cancers (Basel). 12:11172020.
|
|
14
|
Zhang X, Fu X, Dong M, Yang Z, Wu S, Ma M,
Li Z, Wang X, Li L, Li X, et al: Conserved cell populations in
doxorubicin-resistant human nasal natural killer/T cell lymphoma
cell line: Super multidrug resistant cells? Cancer Cell Int.
18:1502018.
|
|
15
|
De Blander H, Morel AP, Senaratne AP,
Ouzounova M and Puisieux A: Cellular plasticity: A route to
senescence exit and tumorigenesis. Cancers (Basel).
13:45612021.
|
|
16
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.
|
|
17
|
Chien Y, Scuoppo C, Wang X, Fang X,
Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, et al:
Control of the senescence-associated secretory phenotype by NF-κB
promotes senescence and enhances chemosensitivity. Genes Dev.
25:2125–2136. 2011.
|
|
18
|
Gilbert LA ands Hemann MT: DNA
damage-mediated induction of a chemoresistant niche. Cell.
143:355–366. 2010.
|
|
19
|
Frasca D, Diaz A, Romero M and Blomberg
BB: Human peripheral late/exhausted memory B cells express a
senescent-associated secretory phenotype and preferentially utilize
metabolic signaling pathways. Exp Gerontol. 87(Pt A): 113–120.
2017.
|
|
20
|
Riley RL, Khomtchouk K and Blomberg BB:
Age-associated B cells (ABC) inhibit B lymphopoiesis and alter
antibody repertoires in old age. Cell Immunol. 321:61–67. 2017.
|
|
21
|
Jia X, Bene J, Balazs N, Szabo K, Berta G,
Herczeg R, Gyenesei A and Balogh P: Age-Associated B cell features
of the murine high-grade B Cell Lymphoma Bc.DLFL1 and its
extranodal expansion in abdominal adipose tissues. J Immunol.
208:2866–2876. 2022.
|
|
22
|
Han S, Georgiev P, Ringel AE, Sharpe AH
and Haigis MC: Age-associated remodeling of T cell immunity and
metabolism. Cell Metab. 35:36–55. 2023.
|
|
23
|
Huang X, Bai X, Cao Y, Wu J, Huang M, Tang
D, Tao S, Zhu T, Liu Y, Yang Y, et al: Lymphoma endothelium
preferentially expresses Tim-3 and facilitates the progression of
lymphoma by mediating immune evasion. J Exp Med. 207:505–520.
2010.
|
|
24
|
Zhang Y, Joe G, Hexner E, Zhu J and
Emerson SG: Host-reactive CD8+ memory stem cells in
graft-versus-host disease. Nat Med. 11:1299–1305. 2005.
|
|
25
|
Zhou B, Zhao Z, Zhang X, Deng W and Li Y:
Effect of allogenic bone marrow mesenchymal stem cell
transplantation on t cells of old mice. Cell Reprogram. 22:30–35.
2020.
|
|
26
|
Chen HC, Eling N, Martinez-Jimenez CP,
O'Brien LM, Carbonaro V, Marioni JC, Odom DT and de la Roche M:
IL-7-dependent compositional changes within the γδ T cell pool in
lymph nodes during ageing lead to an unbalanced anti-tumour
response. EMBO Rep. 20:e473792019.
|
|
27
|
Crespo J, Sun H, Welling TH, Tian Z and
Zou W: T cell anergy, exhaustion, senescence, and stemness in the
tumor microenvironment. Curr Opin Immunol. 25:214–221. 2013.
|
|
28
|
Desdin-Mico G, Soto-Heredero G, Aranda JF,
Oller J, Carrasco E, Gabande-Rodriguez E, Blanco EM, Alfranca A,
Cusso L, Desco M, et al: T cells with dysfunctional mitochondria
induce multimorbidity and premature senescence. Science.
368:1371–1376. 2020.
|
|
29
|
Manser AR and Uhrberg M: Age-related
changes in natural killer cell repertoires: Impact on NK cell
function and immune surveillance. Cancer Immunol Immunother.
65:417–426. 2016.
|
|
30
|
Edwards ESJ, Bier J, Cole TS, Wong M, Hsu
P, Berglund LJ, Boztug K, Lau A, Gostick E, Price DA, et al:
Activating PIK3CD mutations impair human cytotoxic lymphocyte
differentiation and function and EBV immunity. J Allergy Clin
Immunol. 143:276–291.e6. 2019.
|
|
31
|
Prasanna PG, Citrin DE, Hildesheim J,
Ahmed MM, Venkatachalam S, Riscuta G, Xi D, Zheng G, Deursen JV,
Goronzy J, et al: Therapy-Induced Senescence: Opportunities to
improve anticancer therapy. J Natl Cancer Inst. 113:1285–1298.
2021.
|
|
32
|
Milanovic M, Fan DNY, Belenki D, Dabritz
JHM, Zhao Z, Yu Y, Dorr JR, Dimitrova L, Lenze D, Monteiro Barbosa
IA, et al: Senescence-associated reprogramming promotes cancer
stemness. Nature. 553:96–100. 2018.
|
|
33
|
Wang J, Tao Q, Pan Y, Wanyan Z, Zhu F, Xu
X, Wang H, Yi L, Zhou M and Zhai Z: Stress-induced premature
senescence activated by the SENEX gene mediates apoptosis
resistance of diffuse large B-cell lymphoma via promoting
immunosuppressive cells and cytokines. Immun Inflamm Dis.
8:672–683. 2020.
|
|
34
|
Chen LS, Balakrishnan K and Gandhi V:
Inflammation and survival pathways: Chronic lymphocytic leukemia as
a model system. Biochem Pharmacol. 80:1936–1945. 2010.
|
|
35
|
Birch J and Gil J: Senescence and the
SASP: Many therapeutic avenues. Genes Dev. 34:1565–1576. 2020.
|
|
36
|
Braig M, Lee S, Loddenkemper C, Rudolph C,
Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T and
Schmitt CA: Oncogene-induced senescence as an initial barrier in
lymphoma development. Nature. 436:660–665. 2005.
|
|
37
|
Dorr JR, Yu Y, Milanovic M, Beuster G,
Zasada C, Dabritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K,
et al: Synthetic lethal metabolic targeting of cellular senescence
in cancer therapy. Nature. 501:421–425. 2013.
|
|
38
|
Scafuro M, Capasso L, Carafa V, Altucci L
and Nebbioso A: Gene Transactivation and Transrepression in
MYC-Driven Cancers. Int J Mol Sci. 22:34582021.
|
|
39
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008.
|
|
40
|
Cao J, Li L, Chen C, Lv C, Meng F, Zeng L,
Li Z, Wu Q, Zhao K, Pan B, et al: RNA interference-mediated
silencing of NANOG leads to reduced proliferation and self-renewal,
cell cycle arrest and apoptosis in T-cell acute lymphoblastic
leukemia cells via the p53 signaling pathway. Leuk Res.
37:1170–1177. 2013.
|
|
41
|
Reimann M, Lee S, Loddenkemper C, Dorr JR,
Tabor V, Aichele P, Stein H, Dorken B, Jenuwein T and Schmitt CA:
Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via
Suv39h1-dependent senescence. Cancer Cell. 17:262–272. 2010.
|
|
42
|
Moore AR, Rosenberg SC, McCormick F and
Malek S: RAS-targeted therapies: Is the undruggable drugged? Nat
Rev Drug Discov. 19:533–552. 2020.
|
|
43
|
Harrell Stewart DR and Clark GJ: Pumping
the brakes on RAS-negative regulators and death effectors of RAS. J
Cell Sci. 133:jcs2388652020.
|
|
44
|
Moiseeva O, Guillon J and Ferbeyre G:
Senescence: A program in the road to cell elimination and cancer.
Semin Cancer Biol. 81:48–53. 2022.
|
|
45
|
Caceres-Gutierrez RE, Alfaro-Mora Y,
Andonegui MA, Diaz-Chavez J and Herrera LA: The influence of
oncogenic RAS on chemotherapy and radiotherapy resistance through
DNA repair pathways. Front Cell Dev Biol. 10:7513672022.
|
|
46
|
Punekar SR, Velcheti V, Neel BG and Wong
KK: The current state of the art and future trends in RAS-targeted
cancer therapies. Nat Rev Clin Oncol. 19:637–655. 2022.
|
|
47
|
Coppe JP, Patil CK, Rodier F, Sun Y, Munoz
DP, Goldstein J, Nelson PS, Desprez PY and Campisi J:
Senescence-associated secretory phenotypes reveal
cell-nonautonomous functions of oncogenic RAS and the p53 tumor
suppressor. PLoS Biol. 6:2853–2868. 2008.
|
|
48
|
Zhang X, Zhao L, Li X, Wang X, Li L, Fu X,
Sun Z, Li Z, Nan F, Chang Y and Zhang M: ATP-binding cassette
sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell
lymphoma and regulates chemotherapy sensitivity: Potential as a
functional therapeutic target. Leuk Res. 39:1448–1454. 2015.
|
|
49
|
Han L, Long Q, Li S, Xu Q, Zhang B, Dou X,
Qian M, Jiramongkol Y, Guo J, Cao L, et al: Senescent stromal cells
promote cancer resistance through SIRT1 Loss-potentiated
overproduction of small extracellular vesicles. Cancer Res.
80:3383–3398. 2020.
|
|
50
|
Yano H, Fujiwara Y, Horlad H, Pan C, Kai
K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, et al: Blocking
cholesterol efflux mechanism is a potential target for antilymphoma
therapy. Cancer Sci. 113:2129–2143. 2022.
|
|
51
|
Wu S, Zhang X, Dong M, Yang Z, Zhang M and
Chen Q: sATP-binding cassette subfamily G member 2 enhances the
multidrug resistance properties of human nasal natural killer/T
cell lymphoma side population cells. Oncol Rep. 44:1467–1478.
2020.
|
|
52
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13:1652020.
|
|
53
|
Takeda K, Nakayama M, Hayakawa Y, Kojima
Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM and Smyth MJ:
IFN-gamma is required for cytotoxic T cell-dependent cancer genome
immunoediting. Nat Commun. 8:146072017.
|
|
54
|
Islam S, Qi W, Morales C, Cooke L, Spier
C, Weterings E and Mahadevan D: Disruption of aneuploidy and
senescence induced by aurora inhibition promotes intrinsic
apoptosis in double hit or double expressor diffuse large B-cell
lymphomas. Mol Cancer Ther. 16:2083–2093. 2017.
|
|
55
|
Tewari D, Patni P and Bishayee A, Sah AN
and Bishayee A: Natural products targeting the PI3K-Akt-mTOR
signaling pathway in cancer: A novel therapeutic strategy. Semin
Cancer Biol. 80:1–17. 2022.
|
|
56
|
Pi M, Kuang H, Yue C, Yang Q, Wu A, Li Y,
Assaraf YG, Yang DH and Wu S: Targeting metabolism to overcome
cancer drug resistance: A promising therapeutic strategy for
diffuse large B cell lymphoma. Drug Resist Updat.
61:1008222022.
|
|
57
|
Katoh M and Katoh M: Precision medicine
for human cancers with Notch signaling dysregulation (Review). Int
J Mol Med. 45:279–297. 2020.
|
|
58
|
Patil K, Sher G, Kuttikrishnan S, Moton S,
Alam M, Buddenkotte J, Ahmad A, Steinhoff M and Uddin S: The
cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell
lymphoma: Emphasis on therapeutic opportunities. Semin Cell Dev
Biol. 154(Pt C): 239–249. 2024.
|
|
59
|
Weng J, Moriarty KE, Baio FE, Chu F, Kim
SD, He J, Jie Z, Xie X, Ma W, Qian J, et al: IL-15 enhances the
antitumor effect of human antigen-specific CD8(+) T cells by
cellular senescence delay. Oncoimmunology. 5:e12373272016.
|
|
60
|
Wang L, Li LR, Zhang L and Wang JW: The
landscape of new drugs in extranodal NK/T-cell lymphoma. Cancer
Treat Rev. 89:1020652020.
|
|
61
|
Ge H, Ke J, Xu N, Li H, Gong J, Li X, Song
Y, Zhu H and Bai C: Dexamethasone alleviates pemetrexed-induced
senescence in non-small-cell lung cancer. Food Chem Toxicol.
119:86–97. 2018.
|
|
62
|
Ei ZZ, Choochuay K, Tubsuwan A, Pinkaew D,
Suksomtip M, Vinayanuwattikun C, Chanvorachote P and Chunhacha P:
GRP78/BiP determines senescence evasion cell fate after
cisplatin-based chemotherapy. Sci Rep. 11:224482021.
|
|
63
|
Robbins PD, Jurk D, Khosla S, Kirkland JL,
LeBrasseur NK, Miller JD, Passos JF, Pignolo RJ, Tchkonia T and
Niedernhofer LJ: Senolytic Drugs: Reducing senescent cell viability
to extend health Span. Annu Rev Pharmacol Toxicol. 61:779–803.
2021.
|
|
64
|
Azim HA Jr, Pruneri G, Raviele PR,
Steffanoni S, Martinelli G and Peccatori FA: ERCC1 Expression in
Diffuse Large B-Cell lymphoma patients treated with a
cisplatin-based regimen : A brief communication. J Egypt Natl Canc
Inst. 19:176–177. 2007.
|
|
65
|
Lee H: Impaired phosphorylation and
mis-localization of Bub1 and BubR1 are responsible for the
defective mitotic checkpoint function in Brca2-mutant thymic
lymphomas. Exp Mol Med. 35:448–453. 2003.
|
|
66
|
Moncsek A, Al-Suraih MS, Trussoni CE,
O'Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD,
Weber A, et al: Targeting senescent cholangiocytes and activated
fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates
fibrosis in multidrug resistance 2 gene knockout (Mdr2(-/-)) mice.
Hepatology. 67:247–259. 2018.
|
|
67
|
Matthe DM, Thoma OM, Sperka T, Neurath MF
and Waldner MJ: Telomerase deficiency reflects age-associated
changes in CD4+ T cells. Immun Ageing. 19:162022.
|
|
68
|
Reimann M, Loddenkemper C, Rudolph C,
Schildhauer I, Teichmann B, Stein H, Schlegelberger B, Dorken B and
Schmitt CA: The Myc-evoked DNA damage response accounts for
treatment resistance in primary lymphomas in vivo. Blood.
110:2996–3004. 2007.
|
|
69
|
Vidal-Crespo A, Matas-Cespedes A,
Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan-Pla A, Menendez
P, Roue G, Lopez-Guillermo A, et al: Daratumumab displays in vitro
and in vivo anti-tumor activity in models of B-cell non-Hodgkin
lymphoma and improves responses to standard chemo-immunotherapy
regimens. Haematologica. 105:1032–1041. 2020.
|
|
70
|
Fontan L, Goldstein R, Casalena G, Durant
M, Teater MR, Wilson J, Phillip J, Xia M, Shah S, Us I, et al:
Identification of MALT1 feedback mechanisms enables rational design
of potent antilymphoma regimens for ABC-DLBCL. Blood. 137:788–800.
2021.
|
|
71
|
Kim S, Shah SB, Graney PL and Singh A:
Multiscale engineering of immune cells and lymphoid organs. Nat Rev
Mater. 4:355–378. 2019.
|
|
72
|
Tian YF, Ahn H, Schneider RS, Yang SN,
Roman-Gonzalez L, Melnick AM, Cerchietti L and Singh A:
Integrin-specific hydrogels as adaptable tumor organoids for
malignant B and T cells. Biomaterials. 73:110–119. 2015.
|
|
73
|
Ceccato J, Piazza M, Pizzi M, Manni S,
Piazza F, Caputo I, Cinetto F, Pisoni L, Trojan D, Scarpa R, et al:
A bone-based 3D scaffold as an in-vitro model of
microenvironment-DLBCL lymphoma cell interaction. Front Oncol.
12:9478232022.
|
|
74
|
Shah SB, Carlson CR, Lai K, Zhong Z,
Marsico G, Lee KM, Felix Velez NE, Abeles EB, Allam M, Hu T, et al:
Combinatorial treatment rescues tumour-microenvironment-mediated
attenuation of MALT1 inhibitors in B-cell lymphomas. Nat Mater.
22:511–523. 2023.
|
|
75
|
Wyld L, Bellantuono I, Tchkonia T, Morgan
J, Turner O, Foss F, George J, Danson S and Kirkland JL: Senescence
and cancer: A review of clinical implications of senescence and
senotherapies. Cancers (Basel). 12:21342020.
|
|
76
|
Wang B, Li XQ, Ma X, Hong X, Lu H and Guo
Y: Immunohistochemical expression and clinical significance of
P-glycoprotein in previously untreated extranodal NK/T-cell
lymphoma, nasal type. Am J Hematol. 83:795–799. 2008.
|
|
77
|
Wang J, Wang Z, Wang H, Wanyan Z, Pan Y,
Zhu F, Tao Q and Zhai Z: Stress-Induced premature senescence
promotes proliferation by activating the SENEX and
p16(INK4a)/Retinoblastoma (Rb) pathway in diffuse large B-Cell
lymphoma. Turk J Haematol. 36:247–254. 2019.
|
|
78
|
Nguyen PH, Niesen E and Hallek M: New
roles for B cell receptor associated kinases: when the B cell is
not the target. Leukemia. 33:576–587. 2019.
|
|
79
|
Alu A, Lei H, Han X, Wei Y and Wei X: BTK
inhibitors in the treatment of hematological malignancies and
inflammatory diseases: Mechanisms and clinical studies. J Hematol
Oncol. 15:1382022.
|
|
80
|
Chibaya L, Snyder J and Ruscetti M:
Senescence and the tumor-immune landscape: Implications for cancer
immunotherapy. Semin Cancer Biol. 86(Pt 3): 827–845. 2022.
|
|
81
|
Wang X, Zhang L, Liu X, Li X, Li L, Fu X,
Sun Z, Wu J, Zhang X, Yan J, et al: Efficacy and safety of a
pegasparaginase-based chemotherapy regimen vs an
L-asparaginase-Based chemotherapy regimen for newly diagnosed
advanced extranodal natural Killer/T-Cell lymphoma: A randomized
clinical trial. JAMA Oncol. 8:1035–1041. 2022.
|
|
82
|
Kidd JG: Regression of transplanted
lymphomas induced in vivo by means of normal guinea pig serum. II.
Studies on the nature of the active serum constituent: histological
mechanism of the regression: tests for effects of guinea pig serum
on lymphoma cells in vitro: Discussion. J Exp Med. 98:583–606.
1953.
|
|
83
|
Krall AS, Xu S, Graeber TG, Braas D and
Christofk HR: Asparagine promotes cancer cell proliferation through
use as an amino acid exchange factor. Nat Commun. 7:114572016.
|
|
84
|
Wang L, Yang J, Wang HN, Fu RY, Liu XD,
Piao YS, Wei LQ, Wang JW and Zhang L: LncRNA BCYRN1-induced
autophagy enhances asparaginase resistance in extranodal NK/T-cell
lymphoma. Theranostics. 11:925–940. 2021.
|
|
85
|
Zhdanov DD, Pokrovsky VS, Pokrovskaya MV,
Alexandrova SS, Eldarov MA, Grishin DV, Basharov MM, Gladilina YA,
Podobed OV and Sokolov NN: Inhibition of telomerase activity and
induction of apoptosis by Rhodospirillum rubrum L-asparaginase in
cancer Jurkat cell line and normal human CD4+ T lymphocytes. Cancer
Med. 6:2697–2712. 2017.
|
|
86
|
Zhdanov DD, Pokrovsky VS, Pokrovskaya MV,
Alexandrova SS, Eldarov MA, Grishin DV, Basharov MM, Gladilina YA,
Podobed OV and Sokolov NN: Rhodospirillum rubruml-asparaginase
targets tumor growth by a dual mechanism involving telomerase
inhibition. Biochem Biophys Res Commun. 492:282–288. 2017.
|
|
87
|
Hassler MR, Klisaroska A, Kollmann K,
Steiner I, Bilban M, Schiefer AI, Sexl V and Egger G:
Antineoplastic activity of the DNA methyltransferase inhibitor
5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.
Biochimie. 94:2297–2307. 2012.
|
|
88
|
Arosio G, Sharma GG, Villa M, Mauri M,
Crespiatico I, Fonta na D, Ma nf roni C, Mastini C, Zappa M,
Magistroni V, et al: Synergistic drug combinations prevent
resistance in ALK+ anaplastic large cell lymphoma. Cancers (Basel).
13:44222021.
|
|
89
|
Lund K, Adams PD and Copland M: EZH2 in
normal and malignant hematopoiesis. Leukemia. 28:44–49. 2014.
|
|
90
|
Baell JB, Leaver DJ, Hermans SJ, Kelly GL,
Brennan MS, Downer NL, Nguyen N, Wichmann J, McRae HM, Yang Y, et
al: Inhibitors of histone acetyltransferases KAT6A/B induce
senescence and arrest tumour growth. Nature. 560:253–257. 2018.
|
|
91
|
Huang F: New KAT6 inhibitors induce
senescence and arrest cancer growth. Synth Syst Biotechnol.
3:244–245. 2018.
|
|
92
|
Schleich K, Kase J, Dorr JR, Trescher S,
Bhattacharya A, Yu Y, Wailes EM, Fan DNY, Lohneis P, Milanovic M,
et al: H3K9me3-mediated epigenetic regulation of senescence in mice
predicts outcome of lymphoma patients. Nat Commun. 11:36512020.
|
|
93
|
Yin R, Chang J, Li Y, Gao Z, Qiu Q, Wang
Q, Han G, Chai J, Feng M, Wang P, et al: Differential m(6)A RNA
landscapes across hematopoiesis reveal a role for IGF2BP2 in
preserving hematopoietic stem cell function. Cell Stem Cell.
29:149–159 e7. 2022.
|
|
94
|
Mirza N, Duque MA, Dominguez AL, Schrum
AG, Dong H and Lustgarten J: B7-H1 expression on old CD8+ T cells
negatively regulates the activation of immune responses in aged
animals. J Immunol. 184:5466–5474. 2010.
|
|
95
|
Reimann M, Schrezenmeier J,
Richter-Pechanska P, Dolnik A, Hick TP, Schleich K, Cai X, Fan DNY,
Lohneis P, Masswig S, et al: Adaptive T-cell immunity controls
senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood.
137:2785–2799. 2021.
|
|
96
|
Kline J, Godfrey J and Ansell SM: The
immune landscape and response to immune checkpoint blockade therapy
in lymphoma. Blood. 135:523–533. 2020.
|
|
97
|
Wang TW, Johmura Y, Suzuki N, Omori S,
Migita T, Yamaguchi K, Hatakeyama S, Yamazaki S, Shimizu E, Imoto
S, et al: Blocking PD-L1-PD-1 improves senescence surveillance and
ageing phenotypes. Nature. 611:358–364. 2022.
|
|
98
|
Shimada Y, Hayashi M, Nagasaka Y,
Ohno-Iwashita Y and Inomata M: Age-associated up-regulation of a
negative co-stimulatory receptor PD-1 in mouse CD4+ T cells. Exp
Gerontol. 44:517–522. 2009.
|
|
99
|
Lages CS, Lewkowich I, Sproles A,
Wills-Karp M and Chougnet C: Partial restoration of T-cell function
in aged mice by in vitro blockade of the PD-1/PD-L1 pathway. Aging
Cell. 9:785–798. 2010.
|
|
100
|
Tsukamoto H, Komohara Y, Tomita Y, Miura
Y, Motoshima T, Imamura K, Kimura T, Ikeda T, Fujiwara Y, Yano H,
et al: Aging-associated and CD4 T-cell-dependent ectopic CXCL13
activation predisposes to anti-PD-1 therapy-induced adverse events.
Proc Natl Acad Sci USA. 119:e22053781192022.
|
|
101
|
Etxebeste-Mitxeltorena M, Del Rincon-Loza
I and Martin-Antonio B: Tumor secretome to adoptive cellular
immunotherapy: Reduce me before I make you my partner. Front
Immunol. 12:7178502021.
|
|
102
|
Stagni V, Ferri A, Cirotti C and Barila D:
ATM kinase-dependent regulation of autophagy: A key player in
senescence? Front Cell Dev Biol. 8:5990482021.
|
|
103
|
Kang C, Xu Q, Martin TD, Li MZ, Demaria M,
Aron L, Lu T, Yankner BA, Campisi J and Elledge SJ: The DNA damage
response induces inflammation and senescence by inhibiting
autophagy of GATA4. Science. 349:aaa56122015.
|
|
104
|
Bea S, Valdes-Mas R, Navarro A, Salaverria
I, Martin-Garcia D, Jares P, Gine E, Pinyol M, Royo C, Nadeu F, et
al: Landscape of somatic mutations and clonal evolution in mantle
cell lymphoma. Proc Natl Acad Sci USA. 110:18250–18255. 2013.
|
|
105
|
Sarkar A, Stellrecht CM, Vangapandu HV,
Ayres M, Kaipparettu BA, Park JH, Balakrishnan K, Burks JK, Pandita
TK, Hittelman WN, et al: Ataxia-telangiectasia mutated interacts
with Parkin and induces mitophagy independent of kinase activity.
Evidence from mantle cell lymphoma. Haematologica. 106:495–512.
2021.
|
|
106
|
Milanovic M, Shao Z, Estes VM, Wang XS,
Menolfi D, Lin X, Lee BJ, Xu J, Cupo OM, Wang D and Zha S: FATC
domain deletion compromises ATM protein stability, blocks
lymphocyte development, and promotes lymphomagenesis. J Immunol.
206:1228–1239. 2021.
|
|
107
|
Das B, Pal B, Bhuyan R, Li H, Sarma A,
Gayan S, Talukdar J, Sandhya S, Bhuyan S, Gogoi G, et al: MYC
Regulates the HIF2α stemness pathway via Nanog and Sox2 to Maintain
Self-Renewal in cancer stem cells versus non-stem cancer cells.
Cancer Res. 79:4015–4025. 2019.
|
|
108
|
Zhou X, Wen Y, Tian Y, He M, Ke X, Huang
Z, He Y, Liu L, Scharf A, Lu M, et al: Heat Shock Protein
90α-Dependent B-Cell-2-Associated Transcription Factor 1 promotes
hepatocellular carcinoma proliferation by regulating MYC
Proto-Oncogene c-MYC mRNA Stability. Hepatology. 69:1564–1581.
2019.
|
|
109
|
Albakova Z, Mangasarova Y, Albakov A,
Nikulina E, Kravchenko S and Sapozhnikov A: Aberrant HSP90
expression in lymphocytes and HSP90 Response to Anti-PD-1 therapy
in lymphoma patients. Front Immunol. 13:8931372022.
|
|
110
|
Calvo-Vidal MN, Zamponi N, Krumsiek J,
Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E,
Kotlov N, Patel J, et al: Oncogenic HSP90 facilitates metabolic
alterations in aggressive B-cell lymphomas. Cancer Res.
81:5202–5216. 2021.
|
|
111
|
Fuhrmann-Stroissnigg H, Ling YY, Zhao J,
McGowan SJ, Zhu Y, Brooks RW, Grassi D, Gregg SQ, Stripay JL,
Dorronsoro A, et al: Identification of HSP90 inhibitors as a novel
class of senolytics. Nat Commun. 8:4222017.
|
|
112
|
Liu H, Lu Z, Shi X, Liu L, Zhang P,
Golemis EA and Tu Z: HSP90 inhibition downregulates DNA replication
and repair genes via E2F1 repression. J Biol Chem.
297:1009962021.
|
|
113
|
Schmidt L, Issa II, Haraldsdottir H, Hald
JL, Schmitz A, Due H and Dybkaer K: Hsp90 inhibition sensitizes
DLBCL cells to cisplatin. Cancer Chemother Pharmacol. 89:431–440.
2022.
|
|
114
|
Lu Z, Wang Z, Tu Z and Liu H: HSP90
inhibitor ganetespib enhances the sensitivity of mantle cell
lymphoma to bruton's tyrosine kinase inhibitor ibrutinib. Front
Pharmacol. 13:8641942022.
|
|
115
|
He W and Hu H: BIIB021, an Hsp90
inhibitor: A promising therapeutic strategy for blood malignancies
(Review). Oncol Rep. 40:3–15. 2018.
|
|
116
|
Yong K, Cavet J, Johnson P, Morgan G,
Williams C, Nakashima D, Akinaga S, Oakervee H and Cavenagh J:
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with
B-cell malignancies. Br J Cancer. 114:7–13. 2016.
|
|
117
|
Oki Y, Younes A, Knickerbocker J,
Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N,
Kwak L and Westin J: Experience with HSP90 inhibitor AUY922 in
patients with relapsed or refractory non-Hodgkin lymphoma.
Haematologica. 100:e272–e274. 2015.
|
|
118
|
Marumoto T, Zhang D and Saya H: Aurora-A-a
guardian of poles. Nat Rev Cancer. 5:42–50. 2005.
|
|
119
|
Farag SS: The potential role of Aurora
kinase inhibitors in haematological malignancies. Br J Haematol.
155:561–579. 2011.
|
|
120
|
Iqbal J, Weisenburger DD, Chowdhury A,
Tsai MY, Srivastava G, Greiner TC, Kucuk C, Deffenbacher K, Vose J,
Smith L, et al: Natural killer cell lymphoma shares strikingly
similar molecular features with a group of non-hepatosplenic
gammadelta T-cell lymphoma and is highly sensitive to a novel
aurora kinase A inhibitor in vitro. Leukemia. 25:348–358. 2011.
|
|
121
|
Friedberg JW, Mahadevan D, Cebula E,
Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard
EJ, et al: Phase II study of alisertib, a selective Aurora A kinase
inhibitor, in relapsed and refractory aggressive B- and T-cell
non-Hodgkin lymphomas. J Clin Oncol. 32:44–50. 2014.
|
|
122
|
Kelly KR, Friedberg JW, Park SI, McDonagh
K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, et al:
Phase I study of the investigational aurora a kinase inhibitor
alisertib plus rituximab or rituximab/vincristine in
relapsed/refractory aggressive B-cell lymphoma. Clin Cancer Res.
24:6150–6159. 2018.
|
|
123
|
Tan CRC, Abdul-Majeed S, Cael B and Barta
SK: Clinical pharmacokinetics and pharmacodynamics of bortezomib.
Clin Pharmacokinet. 58:157–168. 2019.
|
|
124
|
Robak T, Jin J, Pylypenko H, Verhoef G,
Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G,
et al: Frontline bortezomib, rituximab, cyclophosphamide,
doxorubicin, and prednisone (VR-CAP) versus rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
in transplantation-ineligible patients with newly diagnosed mantle
cell lymphoma: final overall survival results of a randomised,
open-label, phase 3 study. Lancet Oncol. 19:1449–1458. 2018.
|
|
125
|
Teachey DT, Devidas M, Wood BL, Chen Z,
Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August
KJ, et al: Children's Oncology Group Trial AALL1231: A Phase III
clinical trial testing bortezomib in newly diagnosed T-Cell acute
lymphoblastic leukemia and lymphoma. J Clin Oncol. 40:2106–2118.
2022.
|
|
126
|
Hurez V, Dao V, Liu A, Pandeswara S,
Gelfond J, Sun L, Bergman M, Orihuela CJ, Galvan V, Padron A, et
al: Chronic mTOR inhibition in mice with rapamycin alters T, B,
myeloid, and innate lymphoid cells and gut flora and prolongs life
of immune-deficient mice. Aging Cell. 14:945–956. 2015.
|
|
127
|
Major A, Kline J, Karrison TG, Fishkin
PAS, Kimball AS, Petrich AM, Nattam S, Rao K, Sleckman BG, Cohen K,
et al: Phase I/II clinical trial of temsirolimus and lenalidomide
in patients with relapsed and refractory lymphomas. Haematologica.
107:1608–1618. 2022.
|
|
128
|
Borthakur G, Martinelli G, Raffoux E,
Chevallier P, Chromik J, Lithio A, Smith CL, Yuen E, Oakley GJ III,
Benhadji KA and DeAngelo DJ: Phase 1 study to evaluate
Crenigacestat (LY3039478) in combination with dexamethasone in
patients with T-cell acute lymphoblastic leukemia and lymphoma.
Cancer. 127:372–380. 2021.
|
|
129
|
Hart S, Goh KC, Novotny-Diermayr V, Hu CY,
Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, et al:
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the
treatment of myeloid and lymphoid malignancies. Leukemia.
25:1751–1759. 2011.
|
|
130
|
Moskowitz AJ, Ghione P, Jacobsen E, Ruan
J, Schatz JH, Noor S, Myskowski P, Vardhana S, Ganesan N, Hancock
H, et al: A phase 2 biomarker-driven study of ruxolitinib
demonstrates effectiveness of JAK/STAT targeting in T-cell
lymphomas. Blood. 138:2828–2837. 2021.
|
|
131
|
Gillessen S, Pluetschow A, Vucinic V,
Ostermann H, Kobe C, Brockelmann PJ, Boll B, Eichenauer DA, Heger
JM, Borchmann S, et al: JAK inhibition with ruxolitinib in relapsed
or refractory classical Hodgkin lymphoma: Final results of a phase
II, open label, multicentre clinical trial (JeRiCHO). Eur J
Haematol. 109:728–735. 2022.
|
|
132
|
Pullarkat VA, Lacayo NJ, Jabbour E,
Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL,
Fleming SA, et al: Venetoclax and navitoclax in combination with
chemotherapy in patients with relapsed or refractory acute
lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov.
11:1440–1453. 2021.
|
|
133
|
Chang J, Wang Y, Shao L, Laberge RM,
Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W,
et al: Clearance of senescent cells by ABT263 rejuvenates aged
hematopoietic stem cells in mice. Nat Med. 22:78–83. 2016.
|
|
134
|
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai
NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, et al:
Responseadapted anti-PD-1-based salvage therapy for Hodgkin
lymphoma with nivolumab alone or in combination with ICE. Blood.
139:3605–3616. 2022.
|
|
135
|
Nastoupil LJ, Chin CK, Westin JR, Fowler
NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, et al:
Safety and activity of pembrolizumab in combination with rituximab
in relapsed or refractory follicular lymphoma. Blood Adv.
6:1143–1151. 2022.
|
|
136
|
Rybicka M, Zhao J, Piotrowicz K, Ptasnik
S, Mitka K, Kocot-Kępska M and Hui KK: Promoting whole person
health: Exploring the role of traditional Chinese medicine in
Polish healthcare. J Integr Med. 21:509–517. 2023.
|
|
137
|
Luo J, Shen S, Xia J, Wang J and Gu Z:
Mitochondria as the Essence of Yang Qi in the human body.
Phenomics. 2:336–348. 2022.
|
|
138
|
Zhu Y, Tchkonia T, Pirtskhalava T, Gower
AC, Ding H, Giorgadze N, Palmer AK, Ikeno Y, Hubbard GB, Lenburg M,
et al: The Achilles' heel of senescent cells: From transcriptome to
senolytic drugs. Aging Cell. 14:644–658. 2015.
|
|
139
|
Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H,
Dai HM, Ling YY, Stout MB, Pirtskhalava T, Giorgadze N, Johnson KO,
Giles CB, et al: Identification of a novel senolytic agent,
navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
Aging Cell. 15:428–435. 2016.
|
|
140
|
Yoshimura S, Panetta JC, Hu J, Li L, Gocho
Y, Du G, Umezawa A, Karol SE, Pui CH, Mullighan CG, et al:
Preclinical pharmacokinetic and pharmacodynamic evaluation of
dasatinib and ponatinib for the treatment of T-cell acute
lymphoblastic leukemia. Leukemia. 37:1194–1203. 2023.
|
|
141
|
Senapati J, Sasaki K, Issa GC, Lipton JH,
Radich JP, Jabbour E and Kantarjian HM: Management of chronic
myeloid leukemia in 2023-common ground and common sense. Blood
Cancer J. 13:582023.
|
|
142
|
Fujii K, Idogawa M, Suzuki N, Iwatsuki K
and Kanekura T: Functional Depletion of HSP72 by siRNA and
quercetin enhances vorinostat-induced apoptosis in an
HSP72-overexpressing cutaneous T-Cell lymphoma cell line, Hut78.
Int J Mol Sci. 22:112582021.
|
|
143
|
Cai Y, Zhou H, Zhu Y, Sun Q, Ji Y, Xue A,
Wang Y, Chen W, Yu X, Wang L, et al: Elimination of senescent cells
by β-galactosidase-targeted prodrug attenuates inflammation and
restores physical function in aged mice. Cell Res. 30:574–589.
2020.
|
|
144
|
Muralidharan SV, Bhadury J, Nilsson LM,
Green LC, McLure KG and Nilsson JA: BET bromodomain inhibitors
synergize with ATR inhibitors to induce DNA damage, apoptosis,
senescence-associated secretory pathway and ER stress in
Myc-induced lymphoma cells. Oncogene. 35:4689–4697. 2016.
|
